9/15/2008

The FDA's decision to restrict the use of erythropoiesis-stimulating agents in cancer patients with anemia likely will boost the number of blood transfusions in the U.S., said Dr. Laurence Corash, chief medical officer of Cerus Corp. The change is expected to increase demand for the company's products, including the Intercept blood-safety system, which has yet to obtain FDA approval.

Related Summaries